Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases

Lazaros Lekakis, Dimitrios Tryfonopoulos, Nikolaos Pistamatzian, Christos Panopoulos, George Koumakis, Stamatina Demiri, Anna Efremidis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The prognosis of patients with metastatic breast cancer who have failed to respond to at least two different chemotherapy regimens is poor. Such patients with metastatic disease to the liver have even worse prognosis. Cisplatin and 5-fluorouracil (5-FU) can be given in patients with impaired hepatic function but their combination has not been extensively studied in this setting. Patients and Methods: We retrospectively collected data from our registry on patients with advanced metastatic breast cancer who received combination of cisplatin/5-FU. We sought to determine the toxicity, the response rate, the disease control rate and the survival of this combination. Results: We identified 25 heavily pre-treated patients, out of which 19 (76%) had liver metastases. They had been treated before with a median of three lines of cytotoxic chemotherapy. The majority of patients had also received hormonal manipulation or trastuzumab. The median number of cisplatin/5-FU administered cycles, without toxic deaths or unexpected toxicities was four. The partial response (PR) rate was 32% and the disease control rate (DCR) was 68%. The time to progression was five months and the median survival after starting on cisplatin/5-FU was six months. Conclusion: The combination of cisplatin/5-FU is active and safe in heavily pre-treated patients with metastatic breast cancer even in the presence of liver metastases and jaundice.

Original languageEnglish
Pages (from-to)1833-1838
Number of pages6
JournalAnticancer Research
Volume32
Issue number5
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Fluorouracil
Cisplatin
Breast Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Poisons
Jaundice
Registries
Liver Diseases
Survival Rate
Survival

Keywords

  • 5-fluorouracil
  • Breast cancer
  • Cisplatin
  • Liver metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lekakis, L., Tryfonopoulos, D., Pistamatzian, N., Panopoulos, C., Koumakis, G., Demiri, S., & Efremidis, A. (2012). Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. Anticancer Research, 32(5), 1833-1838.

Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. / Lekakis, Lazaros; Tryfonopoulos, Dimitrios; Pistamatzian, Nikolaos; Panopoulos, Christos; Koumakis, George; Demiri, Stamatina; Efremidis, Anna.

In: Anticancer Research, Vol. 32, No. 5, 01.05.2012, p. 1833-1838.

Research output: Contribution to journalArticle

Lekakis, L, Tryfonopoulos, D, Pistamatzian, N, Panopoulos, C, Koumakis, G, Demiri, S & Efremidis, A 2012, 'Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases', Anticancer Research, vol. 32, no. 5, pp. 1833-1838.
Lekakis L, Tryfonopoulos D, Pistamatzian N, Panopoulos C, Koumakis G, Demiri S et al. Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. Anticancer Research. 2012 May 1;32(5):1833-1838.
Lekakis, Lazaros ; Tryfonopoulos, Dimitrios ; Pistamatzian, Nikolaos ; Panopoulos, Christos ; Koumakis, George ; Demiri, Stamatina ; Efremidis, Anna. / Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases. In: Anticancer Research. 2012 ; Vol. 32, No. 5. pp. 1833-1838.
@article{555abff610584175a1ffbb8ce31b5026,
title = "Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases",
abstract = "Background: The prognosis of patients with metastatic breast cancer who have failed to respond to at least two different chemotherapy regimens is poor. Such patients with metastatic disease to the liver have even worse prognosis. Cisplatin and 5-fluorouracil (5-FU) can be given in patients with impaired hepatic function but their combination has not been extensively studied in this setting. Patients and Methods: We retrospectively collected data from our registry on patients with advanced metastatic breast cancer who received combination of cisplatin/5-FU. We sought to determine the toxicity, the response rate, the disease control rate and the survival of this combination. Results: We identified 25 heavily pre-treated patients, out of which 19 (76{\%}) had liver metastases. They had been treated before with a median of three lines of cytotoxic chemotherapy. The majority of patients had also received hormonal manipulation or trastuzumab. The median number of cisplatin/5-FU administered cycles, without toxic deaths or unexpected toxicities was four. The partial response (PR) rate was 32{\%} and the disease control rate (DCR) was 68{\%}. The time to progression was five months and the median survival after starting on cisplatin/5-FU was six months. Conclusion: The combination of cisplatin/5-FU is active and safe in heavily pre-treated patients with metastatic breast cancer even in the presence of liver metastases and jaundice.",
keywords = "5-fluorouracil, Breast cancer, Cisplatin, Liver metastasis",
author = "Lazaros Lekakis and Dimitrios Tryfonopoulos and Nikolaos Pistamatzian and Christos Panopoulos and George Koumakis and Stamatina Demiri and Anna Efremidis",
year = "2012",
month = "5",
day = "1",
language = "English",
volume = "32",
pages = "1833--1838",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Salvage chemotherapy with cisplatin and 5-fluorouracil in metastatic breast cancer. Particular activity against liver metastases

AU - Lekakis, Lazaros

AU - Tryfonopoulos, Dimitrios

AU - Pistamatzian, Nikolaos

AU - Panopoulos, Christos

AU - Koumakis, George

AU - Demiri, Stamatina

AU - Efremidis, Anna

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: The prognosis of patients with metastatic breast cancer who have failed to respond to at least two different chemotherapy regimens is poor. Such patients with metastatic disease to the liver have even worse prognosis. Cisplatin and 5-fluorouracil (5-FU) can be given in patients with impaired hepatic function but their combination has not been extensively studied in this setting. Patients and Methods: We retrospectively collected data from our registry on patients with advanced metastatic breast cancer who received combination of cisplatin/5-FU. We sought to determine the toxicity, the response rate, the disease control rate and the survival of this combination. Results: We identified 25 heavily pre-treated patients, out of which 19 (76%) had liver metastases. They had been treated before with a median of three lines of cytotoxic chemotherapy. The majority of patients had also received hormonal manipulation or trastuzumab. The median number of cisplatin/5-FU administered cycles, without toxic deaths or unexpected toxicities was four. The partial response (PR) rate was 32% and the disease control rate (DCR) was 68%. The time to progression was five months and the median survival after starting on cisplatin/5-FU was six months. Conclusion: The combination of cisplatin/5-FU is active and safe in heavily pre-treated patients with metastatic breast cancer even in the presence of liver metastases and jaundice.

AB - Background: The prognosis of patients with metastatic breast cancer who have failed to respond to at least two different chemotherapy regimens is poor. Such patients with metastatic disease to the liver have even worse prognosis. Cisplatin and 5-fluorouracil (5-FU) can be given in patients with impaired hepatic function but their combination has not been extensively studied in this setting. Patients and Methods: We retrospectively collected data from our registry on patients with advanced metastatic breast cancer who received combination of cisplatin/5-FU. We sought to determine the toxicity, the response rate, the disease control rate and the survival of this combination. Results: We identified 25 heavily pre-treated patients, out of which 19 (76%) had liver metastases. They had been treated before with a median of three lines of cytotoxic chemotherapy. The majority of patients had also received hormonal manipulation or trastuzumab. The median number of cisplatin/5-FU administered cycles, without toxic deaths or unexpected toxicities was four. The partial response (PR) rate was 32% and the disease control rate (DCR) was 68%. The time to progression was five months and the median survival after starting on cisplatin/5-FU was six months. Conclusion: The combination of cisplatin/5-FU is active and safe in heavily pre-treated patients with metastatic breast cancer even in the presence of liver metastases and jaundice.

KW - 5-fluorouracil

KW - Breast cancer

KW - Cisplatin

KW - Liver metastasis

UR - http://www.scopus.com/inward/record.url?scp=84861522825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861522825&partnerID=8YFLogxK

M3 - Article

C2 - 22593470

AN - SCOPUS:84861522825

VL - 32

SP - 1833

EP - 1838

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -